OncoMatch

OncoMatch/Clinical Trials/NCT07723209

Radiation After No Axillary Nodal Sampling

Is NCT07723209 recruiting? Yes, currently enrolling (Sep 2026). This NA trial studies non-drug interventions for early-stage breast cancer.

NARecruitingNYU Langone HealthNCT07723209Data as of Sep 2026

This is a single arm, pilot, prospective study to evaluate the safety of partial breast irradiation in women who undergo breast conserving surgery without sentinel lymph node biopsy (SLNB) or axillary lymph node dissection (ALND). Baseline demographic and clinical information will be collected. All patients will complete the Breast Cancer Treatment Outcome Scale (BCTOS-13) questionnaire and the Functional Assessment of Chronic Illness Therapy-Comprehensive Score for financial Toxicity at baseline and at 2 years. All patients are required to have an axillary ultrasound prior to radiation start if this was not obtained pre-operatively.

Check if I qualify

Extracted eligibility criteria

Cancer type

Breast Carcinoma

Disease stage

Excluded: Stage METASTATIC DISEASE

Metastatic disease [excluded]

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Demographics

Ages ≥ 40
Female only

Structured fields extracted by AI. May contain errors — verify against the official protocol.

US trial sites

  • NYU Langone Health · New York, New York

Showing up to 5 US sites.

See all sites on ClinicalTrials.gov →

Frequently asked questions

Is NCT07723209 currently recruiting?

Yes, this trial is currently recruiting patients.

Is this trial open to male patients?

No. This trial enrolls female patients only.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify